![](/cdn/assets/images/search/clock.png)
We could not find any results for:
Make sure your spelling is correct or try broadening your search.
XOMA Corp is a biotechnology royalty aggregator playing a unique role in helping biotech companies achieve their goal of improving human health. XOMA acquires the potential future economics associated with pre-commercial therapeutic candidates that have been licensed to pharmaceutical or biotechnolo... XOMA Corp is a biotechnology royalty aggregator playing a unique role in helping biotech companies achieve their goal of improving human health. XOMA acquires the potential future economics associated with pre-commercial therapeutic candidates that have been licensed to pharmaceutical or biotechnology companies. When XOMA acquires future economic rights, the seller receives non-dilutive, non-recourse funding that can use to advance their internal drug candidate(s) or for general corporate purposes. Show more
EMERYVILLE, Calif., June 20, 2024 (GLOBE NEWSWIRE) -- XOMA Corporation (Nasdaq: XOMA) (βXOMAβ or the βCompanyβ) today announced its Board of Directors has authorized the following cash dividends...
EMERYVILLE, Calif., June 12, 2024 (GLOBE NEWSWIRE) -- XOMA Corporation (NASDAQ: XOMA), the biotech royalty aggregator, announced today it has received an $8.1 million milestone payment from...
EMERYVILLE, Calif., May 14, 2024 (GLOBE NEWSWIRE) -- XOMA Corporation (NASDAQ: XOMA), the biotech royalty aggregator, announced today that members of its Executive Team will participate in the...
Earned $9 million milestone upon U.S. Food and Drug Administrationβs approval ofΒ Day Oneβs OJEMDAβ’ (tovorafenib);Β XOMA is entitled to receive a mid-single digit royalty on OJEMDAβ’ sales Acquired...
Organon, a global womenβs healthcare company, initiated XACIATOβ’ commercial activities in the fourth quarter of 2023 XOMA further expands its late-stage portfolio with synthetic royalty and...
XOMA is entitled to a mid-single digit royalty on global OJEMDAβ’ sales First and only FDA-approved type II RAF inhibitor for patients with relapsed or refractory pLGG harboring a BRAF fusion or...
Actym Therapeutics Appoints Thomas Smart as CEO PR Newswire BERKELEY, Calif., April 24, 2024 BERKELEY, Calif., April 24, 2024 /PRNewswire/ -- Actym Therapeutics, pioneering a new drug modality to...
EMERYVILLE, Calif., April 03, 2024 (GLOBE NEWSWIRE) -- XOMA Corporation (NASDAQ: XOMA) (βXOMAβ or the βCompanyβ), a biotechnology royalty aggregator playing a distinctive role in helping biotech...
Period β | Change | Change % | Open | High | Low | Avg. Daily Vol | VWAP | |
---|---|---|---|---|---|---|---|---|
1 | 2.47 | 10.0816326531 | 24.5 | 27.05 | 24.5 | 18503 | 26.24511696 | CS |
4 | 2.78 | 11.4923522117 | 24.19 | 27.1 | 21.27 | 33976 | 24.3902377 | CS |
12 | 1.14 | 4.41347270616 | 25.83 | 27.36 | 21.27 | 18226 | 24.66715608 | CS |
26 | 6.97 | 34.85 | 20 | 27.36 | 18.57 | 18985 | 23.9308356 | CS |
52 | 10.46 | 63.3555420957 | 16.51 | 27.36 | 13.48 | 22338 | 19.81430563 | CS |
156 | -5.88 | -17.899543379 | 32.85 | 37.5 | 13.48 | 29443 | 20.75601233 | CS |
260 | 8.81 | 48.513215859 | 18.16 | 46.32 | 13.48 | 37087 | 23.80850582 | CS |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions